Varmx BV has raised €30 million (US$32 million) in an extension to its series B to fund preparations for the pivotal trial of VMX-C001, a modified recombinant factor X that acts as a universal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback